RUCONEST
Total Payments
$6.1M
Transactions
22,196
Doctors
5,050
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $734,735 | 4,964 | 2,198 |
| 2023 | $612,112 | 4,622 | 2,356 |
| 2022 | $603,641 | 3,384 | 1,622 |
| 2021 | $1.3M | 2,242 | 1,059 |
| 2020 | $501,268 | 1,450 | 635 |
| 2019 | $968,869 | 2,348 | 780 |
| 2018 | $933,627 | 1,779 | 540 |
| 2017 | $470,716 | 1,407 | 461 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Honoraria | $2.5M | 920 | 40.5% |
| Unspecified | $1.5M | 39 | 24.4% |
| Consulting Fee | $1.0M | 312 | 16.5% |
| Food and Beverage | $578,980 | 19,297 | 9.5% |
| Travel and Lodging | $402,070 | 1,523 | 6.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $156,984 | 86 | 2.6% |
| Education | $751.04 | 19 | 0.0% |
Payments by Type
General
$4.6M
22,157 transactions
Research
$1.5M
39 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| COVID 19 US Study | Pharming Healthcare, Inc. | $652,517 | 0 |
| Single-site, Open-Label, Pilot Study to Evaluate the Benefit of RUCONEST in Subjects with CVID Who Experience ADRs Related to IVIG Infusions | Pharming Healthcare, Inc. | $167,173 | 0 |
| Treatment of hereditary angioedema prodrom with recombinant human C-1 esterase inhibitor Ruconest | Pharming Healthcare, Inc. | $134,167 | 0 |
| A Phase III,Single Center,Randomized,Double-Blind,Placebo-Controlled Study to Evaluate the Feasibility of Using Human Recombinant C1 InhibitorRUCONEST as a Therapeutic Strategy to Reduce the Incidence of Delayed Graft Function in Recipients of Kidneys From Donation After Cardio-Circulatory Death | Pharming Healthcare, Inc. | $117,443 | 0 |
| Treatment Of Hereditary Angioedema Prodrome With Recombinant Human C1-Esterase Inhibitor Ruconest | Pharming Healthcare, Inc. | $112,874 | 0 |
| CVID-Ruconest A single site open label, study to evaluate the benefits of Ruconest in subjects with CVID who experience ADRs related to IVG infusion | Pharming Healthcare, Inc. | $104,115 | 0 |
| A Randomized, Double Blind, Placebo Controlled, Cross-Over, Proof-of-Concept Study to Evaluate the Benefit of RU CO NEST (Cl Esterase Inhibitor [recombinant]) in Improving Neurological Symptoms in Post-SARS-CoV-2 Infection | Pharming Healthcare, Inc. | $85,000 | 0 |
| VID-Ruconest A single site open label, study to evaluate the benefits of Ruconest in subjects with CVID who experience ADRs related to IVG infusion | Pharming Healthcare, Inc. | $60,875 | 0 |
| Ruconest in DCDD Kidney Transplantation Human recombinant C1 inhibitor as a therapeutic strategy to reduce the incidence of delayed graft function in recipients of kidney from donation after cardio-circulatory death | Pharming Healthcare, Inc. | $50,729 | 0 |
| Consulted with European CoWorkers | Pharming Healthcare, Inc. | $2,220 | 1 |
Top Doctors Receiving Payments for RUCONEST — Page 2
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , DO | Allergy & Immunology | Overland Park, KS | $51,929 | 70 |
| , M.D., | Allergy | Saint Charles, IL | $51,282 | 102 |
| , M. D | Allergy & Immunology | Lakewood, CO | $50,055 | 79 |
| , MD | Internal Medicine | Murray, UT | $48,664 | 103 |
| , PA-C | Medical | Dallas, TX | $39,504 | 85 |
| , MD | Allergy & Immunology | Columbus, OH | $38,735 | 94 |
| , M.D | Allergy & Immunology | Aventura, FL | $33,779 | 66 |
| , PHD, DNP, RN, FNP-BC | Family | Wilmington, DE | $32,336 | 79 |
| , M.D | Pediatrics | Grand Rapids, MI | $30,149 | 50 |
| , M.D | Allergy & Immunology | Houston, TX | $27,155 | 44 |
| , FNP-C | Allergy & Immunology | Scottsdale, AZ | $26,908 | 69 |
| , M.D | Allergy & Immunology | New Haven, CT | $26,531 | 25 |
| , MD, PHD | Allergy & Immunology | Statesville, NC | $24,253 | 24 |
| , DO | Allergy & Immunology | Northampton, MA | $23,343 | 58 |
| , M.D.M.D | Allergy & Immunology | North Charleston, SC | $23,074 | 11 |
| Maziar Rezvani | — | Atlanta, GA | $22,260 | 28 |
| , MD | Allergy & Immunology | Walnut Creek, CA | $20,929 | 82 |
| , MD | Allergy | Tulsa, OK | $19,794 | 52 |
| , M.D | Allergy & Immunology | Iowa City, IA | $17,830 | 17 |
| , M.D | Allergy & Immunology | San Antonio, TX | $17,572 | 51 |
| , MD | Allergy & Immunology | Durham, NC | $16,123 | 20 |
| , M.D | Specialist | Centennial, CO | $14,215 | 33 |
| , M.D | Allergy & Immunology | West Hartford, CT | $13,557 | 18 |
| , MD | Allergy & Immunology | Tacoma, WA | $12,303 | 17 |
| , M.D | Allergy & Immunology | Seattle, WA | $11,158 | 21 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $6.1M
- Total Doctors 5,050
- Transactions 22,196
About RUCONEST
RUCONEST is a drug associated with $6.1M in payments to 5,050 healthcare providers, recorded across 22,196 transactions in the CMS Open Payments database. The primary manufacturer is Pharming Healthcare, Inc..
Payment data is available from 2017 to 2024. In 2024, $734,735 was paid across 4,964 transactions to 2,198 doctors.
The most common payment nature for RUCONEST is "Honoraria" ($2.5M, 40.5% of total).
RUCONEST is associated with 10 research studies, including "COVID 19 US Study" ($652,517).